-
Therapeutics and Clinical Risk Management
-
About Dovepress
Open access peer-reviewed scientific and medical journals.
-
Open Access
Dove Medical Press is now a member of the Open Access Initiative
-
An Author's Guide
A guide to help authors get their paper published.
-
Advocacy
Support Open Access and Dove Press
-
Reprints
Promotional Article Monitoring - further details
-
Favored Author Program
Real benefits for authors, including fast-track processing of papers.
Managing opioid-induced constipation in advanced illness: focus on methylnaltrexone bromide
Review
(2337) Views (1135) Full article downloads
Authors: Katri Elina Clemens, Eberhard Klaschik
Published Date February 2010
Volume 2010:6 Pages 77 - 82
DOI: http://dx.doi.org/10.2147/TCRM.S4301
Katri Elina Clemens1,2, Eberhard Klaschik1
1Department of Science and Research, Centre for Palliative Medicine, University of Bonn, Germany; 2Department of Palliative Medicine and Pain Therapy, Malteser Hospital Bonn/Rhein-Sieg, Germany
Abstract: Constipation is a common symptom in palliative care patients which can generate considerable suffering. There is uncertainty about the choice of treatment options from varying recommendations for management of constipation and a varying clinical practice in palliative care settings. The purpose of the review was to evaluate the current recommendations of therapy guidelines for the management of opioid-induced constipation in palliative care patients with a focus on methylnaltrexone bromide. Recent findings in the literature and related information on the opioid-induced gastrointestinal disorders in patients with advanced illness, as well as information on the opioid-antagonist methylnaltrexone, are discussed. Knowledge of the role of definitions, the causes of constipation and the pathophysiology of opioid-induced constipation must be given high priority in the treatment of patients receiving opioids. Diagnosis and therapy of constipation, therefore, should relate to findings in clinical investigation. Opioid-induced constipation and its adequate treatment is an important issue for patients with advanced illness and also poses therapeutic challenge for clinicians in daily routine. Methylnaltrexone bromide may represent an important therapeutic option for palliative care patients who are suffering from opioid-induced constipation with failure of conventional prophylactic oral laxative treatment.
Keywords: opioid-induced constipation, palliative care, opioids, methylnaltrexone bromide
- Have an opinion about one of our articles?
We encourage you to write a Letter to the Editor
- American Acne and Rosacea Society
The American Acne and Rosacea Society (AARS), is a 501(c)(6) non-profit organization dedicated to elevating the understanding and treatment of acne and rosacea.
- Tenofovir-associated bone density loss
- The benefits and risks of testosterone replacement therapy: a review
- Drug design with Cdc7 kinase: a potential novel cancer therapy target
- Development of mucosal adjuvants for intranasal vaccine for H5N1 influenza viruses




